Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1445427

Case Report: Tenosynovial Giant Cell Tumor

Provisionally accepted
Anke Fähnrich Anke Fähnrich 1*Zhala Gasimova Zhala Gasimova 2Yamil Yamil Maluje Yamil Yamil Maluje 1Fabian Ott Fabian Ott 1Helen Sievert Helen Sievert 2Stephanie Fliedner Stephanie Fliedner 2Niklas Reimer Niklas Reimer 1Axel Künstner Axel Künstner 1Niklas Gebauer Niklas Gebauer 2Maxim Kebenko Maxim Kebenko 2Nikolas vonBubnoff Nikolas vonBubnoff 2Jutta Kirfel Jutta Kirfel 3Verena sailer Verena sailer 3Christoph Röcken Christoph Röcken 4Bjoern Konukiewitz Bjoern Konukiewitz 4Wolfram Klapper Wolfram Klapper 5Alex Frydrychowicz Alex Frydrychowicz 6Sam Mogadas Sam Mogadas 6Gerdt Huebner Gerdt Huebner 7Hauke Busch Hauke Busch 1Cyrus Khandanpour Cyrus Khandanpour 2
  • 1 Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Schleswig-Holstein, Germany
  • 2 Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Lübeck, Germany
  • 3 Institut für Pathologie, Universität zu Lübeck, Luebeck, Germany
  • 4 Department of Pathology, Christian-Albrechts-University, Kiel, Germany, Kiel, Germany
  • 5 Institut for Haematopathology, Christian-Albrechts-University, Kiel, Germany
  • 6 Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Luebeck, Germany
  • 7 Ostholstein Onkologie & Ameos Klinikum, Eutin, Germany

The final, formatted version of the article will be published soon.

    Tenosynovial giant cell tumor (TGCT) is a rare type of tumor that originates from the synovium of joints and tendon sheaths. It is characterized by recurring genetic abnormalities, often involving the CSF1 gene. Common symptoms include pain and swelling, which are not specific to TGCT, so MRI and a pathological biopsy are needed for an accurate diagnosis.
We report the case of a 45-year-old man who experienced painful swelling in his right hip for six months. Initially, this was diagnosed as Erdheim-Chester disease. However, whole exome sequencing (WES) and RNA sequencing revealed a CSF1::GAPDHP64 fusion, leading to a revised diagnosis of TGCT. The patient was treated with pegylated interferon and imatinib, which resulted in stable disease after three months.
Single-cell transcriptome analysis identified seven distinct cell clusters, revealing that neoplastic cells expressing CSF1 attract macrophages. Analysis of ligand-receptor interactions showed significant communication between neoplastic cells and macrophages mediated by CSF1 and CSF1R. Our findings emphasize the importance of comprehensive molecular analysis in the diagnosis and treatment of rare malignancies like TGCT.

    Keywords: Single cell sequencing (scRNA-seq), RNA-Seq - RNA sequencing, CSF1 fusion transcript, Tenosynovial giant cell tumor (TGCT), Molecular tumor board (MTB)

    Received: 07 Jun 2024; Accepted: 06 Sep 2024.

    Copyright: © 2024 Fähnrich, Gasimova, Yamil Maluje, Ott, Sievert, Fliedner, Reimer, Künstner, Gebauer, Kebenko, vonBubnoff, Kirfel, sailer, Röcken, Konukiewitz, Klapper, Frydrychowicz, Mogadas, Huebner, Busch and Khandanpour. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Anke Fähnrich, Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, 23538, Schleswig-Holstein, Germany

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.